CD44 and familial pancreatic carcinoma: Thus, CD133, EpCAM, CD44, and CXCR4 are commonly used to isolate and examine the involvement of the CSC population in pancreatic cancer progression [33,65,66,67] and constitute prime targets for the treatment.